Novartis AG
NVSHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, Novartis AG (NVS) is listed under Drug Manufacturers - General. The $293.39B market capitalization puts NVS squarely in mega-cap range for its industry. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
Market Cap
$293.39B
Beta
0.49
P/E (TTM)
21.87
P/E (Fwd)
15.77
EPS (TTM)
$7.03
EPS (Fwd)
$9.75
ROE
34.9%
ROA
10.5%
Cash
$6.89B
Total Debt
$47.00B
Free CF
$12.02B
52W Change
34.6%
Annual Financials
Cash vs Debt
The company holds $6.89B in cash, though total debt stands at $47.00B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $12.02B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 34.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.5% further supports the picture of efficient asset utilization. Revenue has grown from $43.46B (2022) to $56.67B (2025), reflecting a 30% increase over the period.
With a beta below 0.7, Novartis AG typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Novartis AG's trajectory.